Showing results (431-440 of 504) with videos related to

Sort By:
Pageof 51
BMC Pulmonary Medicine|January 24, 2016
Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repositoryE L Crawford, A Levin, F Safi, et al.
The New England Journal of Medicine|May 20, 2014
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisTalmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, et al.
The Oncologist|March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumorsChooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
The European Respiratory Journal|May 29, 2024
Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study resultsSteven D Nathan, Rahul Argula, Maria G Trivieri, et al.
BMJ Open Respiratory Research|February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsLisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
The European Respiratory Journal|December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Pulmonary Circulation|August 26, 2022
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertensionSylvia M Nikkho, Manuel J Richter, Eric Shen, et al.
The European Respiratory Journal|March 7, 2020
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registryOksana A Shlobin, Vasilis Kouranos, Scott D Barnett, et al.
Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 1, 2022
Clinical features and allograft failure rates of pulmonary antibody-mediated rejection categoriesAnanth V Charya, Ileana L Ponor, Adam Cochrane, et al.
Pageof 51